TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - You must be female and at least 18 years old. - You must have been diagnosed with breast cancer. - Your pre-study lab tests are within study requirements. - You must be willing to take folic acid and vitamin B12. Exclusion Criteria: - You are pregnant or breastfeeding. - You have another illness that your doctor thinks would make you unable to participate. - You are currently taking aspirin or aspirin-like medicine and are unable to stop for a few days during each cycle of therapy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed 600 mg/m2 (Type: EXPERIMENTAL): None
- Pemetrexed 1800 mg/m2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 1 urinary urgency episode/24h (on average) documented in a 3-day patient diary in the screening phase with or without urge incontinence, and usually with frequency and nocturia, described as OAB~* Patients may be included if they were never exposed to anticholinergic agents specified for the treatment of OAB. Patients may also be included if they have previously been treated with FDA-approved anticholinergic agents for the treatment of OAB such as oxybutynin chloride and are no longer receiving such treatment for a minimum of 14 days immediately preceding entry into the study. These previously treated patients must present at the investigative site on no anticholinergic agents and with the desire to receive treatment for OAB. Previous non-drug treatment of OAB is allowed if it has been established at least 4 weeks prior to study entry and is continued throughout the study.~* Patients having urgency with or without urge incontinence accompanied by frequency of ≥8 episodes per 24 hours, and/or nocturia, for a period of ≥3 months prior to screening.~Exclusion Criteria:~* Previous treatment with darifenacin~* Duration of urgency with or without urge incontinence, usually accompanied with frequency and nocturia for \<3 months~* Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the Investigator~* Evidence of a urinary tract infection; chronic inflammation such as interstitial cystitis and bladder stones~* Clinically significant outflow obstruction (benign prostatic hyperplasia) as determined by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Continuous Use Of Celecoxib Vs. Usual or Intermittent Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has been diagnosed, according to American College of Rheumatology guidelines, with osteoarthritis of the hip or knee and requires non-steroidal anti-inflammatory drugs (NSAIDs) to control their osteoarthritis pain and have access to a touch-tone telephone.~Exclusion Criteria:~* Subject has had surgery on index joint.~* Subject has history of rheumatoid arthritis or fibromyalgia syndrome.~* Subject has active gastrointestinal or cardiovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib - Continuous use (Type: ACTIVE_COMPARATOR): None
- Celecoxib - Intermittent use (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated, written informed consent prior to any study-specific procedures.~* Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture; female subjects must be post menopausal or surgically sterile.~* Male subjects should be willing to use barrier contraception ie, condoms, from the first day of the investigational product administration until 3 months after the last administration of the investigational product.~* Have a body mass index (BMI) between 19 and 30 kg/m2~* Be able to understand and willing to comply with study procedures, restrictions, and requirements, as judged by the Investigator~Exclusion Criteria:~* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study~* History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs~* Known history of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious reaction to carbapenem or cephalosporin antibiotics or other beta-actam antibiotics or any other investigational product to be administered as part of the study~* Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks prior to the first administration of investigational product Any clinically significant abnormalities in physical examination, ECG, clinical chemistry, haematology, or urinalysis results, as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- CAZAVI (Type: EXPERIMENTAL): CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)
- Metronidazole (Type: ACTIVE_COMPARATOR): Metronidazole (500 mg)
- CAZAVI+metronidazole (Type: ACTIVE_COMPARATOR): CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine with or without aura for \> 1 year~* Average of 1 to 6 moderate or severe migraines per month for 2 months before entering the study~* Untreated migraines lasting at least 4 hours~* At least 24 hours between migraines~* Able to tell the difference between migraines and other types of headache~* If female, using birth control~Exclusion Criteria:~* Chronic tension or cluster headache~* Prolonged aura~* Specific types of migraine~* \> 6 nonmigraine headaches per month~* High blood pressure for the age~* Medical history with specific significant conditions affecting the liver, kidney, heart or other body systems~* Conditions that might affect the way the body absorbs or processes a drug~* Positive blood tests for Hepatitis B or C~* Recent head or neck injury~* Body weight outside given parameters~* Unable to take sumatriptan~* Abusing drugs or alcohol~* Pregnant or breast-feeding~* Use of antimigraine medication that might interfere with the study, of antimigraine medication for \< 2 weeks, of lithium or monoamine oxidase inhibitors in past 2 weeks, of an investigational drug within 2 months~* Refuse to abstain from taking medicine with ergotamine or any other drug like almotriptan within 48 hours before and 24 hours after taking study medication, or drugs containing opiates or antivomiting medicine within 48 hours before and 2 hours after taking study medication~* Use of simple pain medicines within 24 hours (like aspirin)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Safety Study Of Maraviroc

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with limited or no approved treatment options available to them due to resistance or intolerance;~* Subjects must be failing to achieve adequate virologic suppression on their current regimen and have HIV-1 RNA ≥ 1000 copies/ml, at screening.~* Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay.~Exclusion Criteria:~* Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trials or having previously discontinued Maraviroc in trials~* Potentially life threatening (Grade 4) laboratory abnormality or medical condition (according to the Division of AIDS table for grading severity of adult adverse experiences) still under investigation unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and Pfizer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of heart failure~* Recent echocardiogram documenting left ventricular ejection fraction \<40%~* High sensitivity C-reactive protein \>2 mg/L.~Exclusion Criteria:~* Recent changes (previous 3 months) in HF maintenance medications (beta-blockers, angiotensin converting enzyme \[ACE\] inhibitors, aldosterone antagonists, vasodilators, cardiac glycosides, diuretics)~* Hospitalization for worsening HF or acute decompensated HF within the previous 12 months~* Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable cardioverter defibrillator (AICD)~* Angina or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing or baseline ECG changes that limit the ability to detect ischemia (i.e. left bundle-branch block).~* Recent (\<14 days) use of anti-inflammatory drugs (not including NSAIDs), chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus), malignancy, active infection, or any comorbidity limiting survival or ability to complete the study~* Severe kidney dysfunction (eGFR \<30 mL/min)~* Coagulopathy (INR \>1.5), thrombocytopenia (\<50,000/mm3), or leukopenia (absolute neutrophil count \<1,500/mm3)~* Pregnancy (female patients will be required to take a urine pregnancy test)~* Latex or rubber allergy~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Scan Reader Criteria (5 total readers):~* Board-certified in radiology or nuclear medicine~* Professional experience interpreting PET scans~Scan Criteria (205 total scans):~* Former enrollment in AZES Study~* Flortaucipir scan at baseline~* clinical dementia rating - sum of boxes (CDR-SB) assessment at 18 months~Scan Study Population (AZES Study):~* 55 to 85 years~* MCI due to AD or probable AD by National Institute on Aging-Alzheimer's Association criteria (Albert 2011~* mini-mental status exam (MMSE) of 20 to 30 inclusive~* CDR global score of 0.5 (MCI), or 0.5 or 1 (AD) with a memory box score ≥ 0.5, and a score of ≤85 on the Delayed Memory Index of the Repeatable Battery for the Assessment of Neuropsychological Status.~* Amyloid positive status confirmed by florbetapir PET or lumbar puncture

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Flortaucipir PET Scan (Type: EXPERIMENTAL): No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have histologically confirmed and newly diagnosed operable breast cancer~* HER2 positive (all FISH +)~* Axillary node positive (by PET or cytologically determine node by sonography) and/or tumor size \> 5 cm -No prior hormonal, chemotherapy or radiotherapy is allowed.~* No breast operation other than biopsy to make diagnosis is allowed.~* Age: 18-years and older, not pregnant pre-, and postmenopausal women with good performance status (ECOG 0-1)~* Adequate hematopoietic function:~Absolute granulocyte count ³1500/mm3,~* platelet ³100,000/mm3, Hemoglobin ³ 10 g/mm3~* Adequate renal function: Serum creatinine £ 1.5 mg/dl~* Adequate hepatic function: total bilirubin: £ 1.5 mg/dl, AST/ALT: £ 2 times normal, Alkaline phosphatase: £ 2 times normal-Adequate cardiac function:~  1. normal or nonspecific EKG taken within 1 mo of enrollment~ 2. LVEF ³ 50% by MUGA or Echocardiogram taken within 1 mo of enrollment~* Normal mental function to understand and sign the consent~Exclusion Criteria:~* patients who received hormonal, chemotherapy or radiotherapy for breast cancer~* patients who underwent surgery for breast cancer~* patients with a history of uncompensated congestive heart failure~* Patients with node-negative stage IIA (T2N0) breast cancer~* Patients who have history of cancer other than in situ uterine cervix cancer or nonmelanotic skin cancer

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel/Gemcitabine/Trastuzumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women above the age of 50 years with the diagnosis of postmenopausal primary osteoporosis may be enrolled in the trial if the following inclusion/exclusion criteria apply.~All inclusion criteria must be answered yes for a subject to be enrolled in the trial.~1. Has the subject given informed consent according to local requirements before any trial related activities? (A trial related activity is any procedure that would not have been performed during the routine management of the subject).~2. Is the subject above 50 years old?~3. Is the subject postmenopausal (more than 5 years) - in the judgement of the investigator?~4. Does the subject have primary osteoporosis with a lumbar spine T score \< -3.0 SD (at lumbar spine L1-L4, with a minimum of two evaluable vertebrae)?~5. Does the subject have a life expectancy of \>3 years?~6. Is the subject able to self-inject PTH (1-84), (or to have PTH (1-84) injection by a helper)?

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTH (1-84) (Type: EXPERIMENTAL): None
- Risedronate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfills at least 4 of the 11 American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE) including a positive antinuclear antibody (ANA) greater than or equal to 1:80 or elevated anti-double-stranded DNA or anti-Smith antibody at screening~* Pediatric or adult SLE with chronic disease activity for greater than or equal to 24 weeks~* Weight greater than or equal to 40 kg~* Currently receiving stable dose of oral prednisone (or equivalent) less than or equal to 40 mg/day and/or antimalarials/immunosuppressives~* Active moderate to severe SLE disease based on SLE disease activity score (SLEDAI) and British Isles Lupus Assessment Group Index (BILAG) and Physicians Global Assessment~* No evidence of cervical malignancy on Pap smear within 2 years of randomization~* Female participants must be willing to avoid pregnancy~* Negative tuberculosis (TB) test or newly positive TB test due to latent TB for which treatment must be initiated at or before randomization.~Exclusion Criteria:~* Active severe SLE-driven renal disease or unstable renal disease prior to screening~* Active severe or unstable neuropsychiatric SLE~* Clinically significant active infection including ongoing and chronic infections~* History of human immunodeficiency virus (HIV)~* Confirmed Positive tests for hepatitis B or positive test for hepatitis C~* History of severe herpes infection such as herpes encephalitis, ophthalmic herpes, disseminated herpes~* Live or attenuated vaccine within 4 weeks prior to screening~* Participants with significant hematologic abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Anifrolumab (MEDI-546) 300 mg (Type: EXPERIMENTAL): Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
- Anifrolumab (MEDI-546) 1000 mg (Type: EXPERIMENTAL): Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
- Matching Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylatic Effect Preoperative Antibiotics With Mechanical Bowel Preparation in SSIs: A Propensity Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient underwent elective colorectal resection to treat a malignancy;~2. Patient baseline characteristics and operative information were available;~3. MBP (mechanical bowel preparation) was performed before surgery, with or without OA (oral antibiotics).~Exclusion Criteria:~1. Emergency surgery;~2. MBP was not conducted due to ileus or patient refusal;~3. Enough data was not available;~4. Colorectal resection was performed due to benign disease;~5. The procedure was accompanied by other procedures that had the potential to contaminate the incision, such as cholecystectomy or appendectomy;~6. Patients underwent neoadjuvant radiotherapy before surgery.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OA+MBP group (Type: None): Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
- MBP group (Type: None): Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. No oral antibiotics was administered to the patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete